QVA149 versus glycopyrronium for COPD

Lancet Respir Med. 2013 Jul;1(5):e22-3. doi: 10.1016/S2213-2600(13)70115-2. Epub 2013 Jul 8.

Authors

Alain Van Meerhaeghe¹, Michel Vanhaeverbeek²

Affiliations

¹ CHU-Charleroi, 6110, Charleroi, Belgium. Electronic address: alain.vanmeerhaeghe@chu-charleroi.be.
² CHU-Charleroi, 6110, Charleroi, Belgium.

PMID: 24429209
DOI: 10.1016/S2213-2600(13)70115-2

No abstract available

Publication types

Letter
Comment

MeSH terms

Female
Glycopyrrolate / analogs & derivatives*
Humans
Indans*
Male
Pulmonary Disease, Chronic Obstructive / drug therapy*
Quinolones*
Respiratory System / drug effects*
Scopolamine Derivatives*

Substances

Indans
Quinolones
Scopolamine Derivatives
Glycopyrrolate